Related Experiment Videos
[Asthma: bronchial inflammation and hyperreactivity]
M A Baeza-Bacab1, J J Sienra-Monge
1Departamento de Educación Médica Continua, Facultad de Medicina, Universidad Autónoma de Yucatán, Merida, México.
Boletin Medico Del Hospital Infantil De Mexico
|November 1, 1993
Summary
Asthma involves reversible bronchial obstruction and inflammation. New treatments focus on controlling bronchial hyperreactivity and managing both early-phase (using bronchodilators) and late-phase asthma symptoms.
Area of Science:
- Pulmonology
- Allergology
- Immunology
Context:
- Asthma is characterized by reversible airway obstruction and bronchial hyperreactivity (BHR).
- Inflammation plays a critical role in exacerbating BHR and the progression of asthma.
- Current understanding acknowledges distinct early and late phases in asthma pathophysiology.
Purpose:
- To define asthma, focusing on reversible bronchial obstruction, BHR, and inflammation.
- To explore emerging treatment strategies targeting BHR and the dual phases of asthma.
- To outline optimal pharmacological approaches for managing asthma's immediate and sustained inflammatory components.
Summary:
- Asthma is commonly defined by reversible airway obstruction, increased bronchial hyperreactivity (BHR), and underlying inflammation.
- Inflammation contributes to heightened BHR, worsening the asthmatic condition.
- Modern asthma management aims to control BHR and address both early-phase (immediate) and late-phase reactions.
Impact:
- Provides a clear, concise overview of asthma definition and pathophysiology.
- Highlights the importance of targeting bronchial hyperreactivity in asthma management.
- Differentiates treatment strategies for early-phase (bronchodilators) and late-phase (anti-inflammatories) asthma.